☰

Keyi Zhu, Ph.D. - Publications

Affiliations: 
2007 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 White MC, Schroeder RD, Zhu K, Xiong K, McConkey DJ. HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene. PMID 29720726 DOI: 10.1038/S41388-018-0227-Y  0.667
2016 Jia H, Song L, Cong Q, Wang J, Xu H, Chu Y, Li Q, Zhang Y, Zou X, Zhang C, Chin YE, Zhang X, Li Z, Zhu K, Wang B, et al. The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network. Oncogene. PMID 27893714 DOI: 10.1038/Onc.2016.418  0.461
2016 Jinesh GG, Mokkapati S, Zhu K, Morales EE. Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks. Apoptosis : An International Journal On Programmed Cell Death. PMID 27651368 DOI: 10.1007/S10495-016-1289-3  0.517
2010 Zhu K, Dunner K, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 29: 451-62. PMID 19881538 DOI: 10.1038/Onc.2009.343  0.684
2009 Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ. Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Research. 69: 1836-43. PMID 19244104 DOI: 10.1158/0008-5472.Can-08-4103  0.538
2008 McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 11: 164-79. PMID 18818117 DOI: 10.1016/J.Drup.2008.08.002  0.657
2006 Canfield SE, Zhu K, Williams SA, McConkey DJ. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Molecular Cancer Therapeutics. 5: 2043-50. PMID 16928825 DOI: 10.1158/1535-7163.Mct-05-0437  0.707
2006 Zhu K, Pino M, Siefker-Radtke AO, Shalinsky D, Hu-Lowe D, McConkey DJ. AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo. Journal of Clinical Oncology. 24: 13109-13109. DOI: 10.1200/Jco.2006.24.18_Suppl.13109  0.543
2005 Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Research. 65: 4902-8. PMID 15930312 DOI: 10.1158/0008-5472.Can-04-3701  0.43
Show low-probability matches.